{"id":127628,"date":"2026-06-23T13:23:08","date_gmt":"2026-06-23T07:53:08","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=127628"},"modified":"2026-06-23T13:23:10","modified_gmt":"2026-06-23T07:53:10","slug":"nifty-pharma-jumps-june-23-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/nifty-pharma-jumps-june-23-2026\/","title":{"rendered":"Nifty Pharma Jumps Nearly 2% on June 23, 2026: Dr Reddy&#8217;s, Sun Pharma and Cipla Lead Gains"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Nifty Pharma: 25,191 (+1.73%, high 25,294.50). Cipla +2.51% to Rs 1,451. Dr Reddy&#8217;s +1.68% Rs 1,312. Sun Pharma +1.50% Rs 1,891. Divi&#8217;s Lab +0.76% Rs 6,839. Nifty IT -1.80%.<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/indices\/nifty-pharma\/nifty-pharma-share-price-today\">Nifty Pharma<\/a> is the best-performing sectoral index on June 23, 2026, rising 1.73% to 25,191 and hitting a session high of 25,294.50, as pharmaceutical stocks attract defensive buying while the <a href=\"https:\/\/univest.in\/indices\/niftyit\/nifty-it-share-price-today\">Nifty IT<\/a> index falls 1.80% and the <a href=\"https:\/\/univest.in\/indices\/nifty-50\/nifty-50-share-price-today\">Nifty 50<\/a> trades near flat at 24,104. The index&#8217;s top contributors today are <a href=\"https:\/\/univest.in\/stocks\/cipla\/cipla-ltd-share-price-today\">Cipla<\/a> (+2.51% to Rs 1,451.20), <a href=\"https:\/\/univest.in\/stocks\/drreddy\/dr-reddys-laboratories-ltd-share-price-today\">Dr Reddy&#8217;s<\/a> (+1.68% to Rs 1,312.40), and <a href=\"https:\/\/univest.in\/stocks\/sunpharma\/sun-pharmaceutical-industries-ltd-share-price-today\">Sun Pharma<\/a> (+1.50% to Rs 1,890.80), with <a href=\"https:\/\/univest.in\/stocks\/divislab\/divis-laboratories-ltd-share-price-today\">Divi&#8217;s Laboratories<\/a> also positive at +0.76% (Rs 6,839). All four pharma names rank among the top Nifty 50 gainers today.<\/p>\n<p>The rally reflects a classic defensive sector rotation: investors moving capital from IT stocks, which are sensitive to US rate cycles and global tech spending, into healthcare names with steady domestic prescription revenue and an active US generics approval pipeline. Kunal Singla, Associate Director at Univest notes that Nifty Pharma&#8217;s outperformance by nearly 3.5 percentage points over Nifty IT today is one of the most pronounced intraday sector divergences in recent sessions, driven by the combination of the global AI trade selloff (weighing on IT) and the Fed hawkishness (which benefits defensive healthcare allocation).<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=nifty-pharma-jumps-june-23-2026\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/nifty-pharma-jumps-june-23-2026\/#Nifty_Pharma_Gainers_June_23_Key_Stock_Data\" title=\"Nifty Pharma Gainers June 23: Key Stock Data\">Nifty Pharma Gainers June 23: Key Stock Data<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/nifty-pharma-jumps-june-23-2026\/#Key_Drivers_of_Todays_Rally\" title=\"Key Drivers of Today&#8217;s Rally\">Key Drivers of Today&#8217;s Rally<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/nifty-pharma-jumps-june-23-2026\/#1_Cipla_Leads_the_Pharma_Pack_with_251_Gain\" title=\"1. Cipla Leads the Pharma Pack with 2.51% Gain\">1. Cipla Leads the Pharma Pack with 2.51% Gain<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/nifty-pharma-jumps-june-23-2026\/#2_Dr_Reddys_and_Sun_Pharma_The_Nifty_Pharma_Pillars\" title=\"2. Dr Reddy&#8217;s and Sun Pharma: The Nifty Pharma Pillars\">2. Dr Reddy&#8217;s and Sun Pharma: The Nifty Pharma Pillars<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/nifty-pharma-jumps-june-23-2026\/#3_Defensive_Rotation_Narrative_IT_Outflows_Fund_Pharma_Inflows\" title=\"3. Defensive Rotation Narrative: IT Outflows Fund Pharma Inflows\">3. Defensive Rotation Narrative: IT Outflows Fund Pharma Inflows<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/nifty-pharma-jumps-june-23-2026\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/nifty-pharma-jumps-june-23-2026\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/nifty-pharma-jumps-june-23-2026\/#Why_is_Nifty_Pharma_rising_today\" title=\"Why is Nifty Pharma rising today?\">Why is Nifty Pharma rising today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/nifty-pharma-jumps-june-23-2026\/#What_is_Nifty_Pharma_today\" title=\"What is Nifty Pharma today?\">What is Nifty Pharma today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/nifty-pharma-jumps-june-23-2026\/#Which_pharma_stocks_are_rising_today\" title=\"Which pharma stocks are rising today?\">Which pharma stocks are rising today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/nifty-pharma-jumps-june-23-2026\/#Why_is_Cipla_rising\" title=\"Why is Cipla rising?\">Why is Cipla rising?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/nifty-pharma-jumps-june-23-2026\/#Why_is_Nifty_IT_falling_while_Nifty_Pharma_rises\" title=\"Why is Nifty IT falling while Nifty Pharma rises?\">Why is Nifty IT falling while Nifty Pharma rises?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/nifty-pharma-jumps-june-23-2026\/#What_is_Sun_Pharmas_performance_today\" title=\"What is Sun Pharma&#8217;s performance today?\">What is Sun Pharma&#8217;s performance today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/nifty-pharma-jumps-june-23-2026\/#Is_Nifty_Pharma_a_good_investment\" title=\"Is Nifty Pharma a good investment?\">Is Nifty Pharma a good investment?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/nifty-pharma-jumps-june-23-2026\/#What_is_Divis_Laboratories\" title=\"What is Divi&#8217;s Laboratories?\">What is Divi&#8217;s Laboratories?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Nifty_Pharma_Gainers_June_23_Key_Stock_Data\"><\/span><strong>Nifty Pharma Gainers June 23: Key Stock Data<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<thead>\n<tr>\n<th>Stock<\/th>\n<th>Price (Rs)<\/th>\n<th>Prev Close<\/th>\n<th>Change<\/th>\n<th>% Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Cipla<\/td>\n<td>1,451.20<\/td>\n<td>1,415.70<\/td>\n<td>+35.50<\/td>\n<td>+2.51%<\/td>\n<\/tr>\n<tr>\n<td>Dr Reddy&#8217;s<\/td>\n<td>1,312.40<\/td>\n<td>1,290.70<\/td>\n<td>+21.70<\/td>\n<td>+1.68%<\/td>\n<\/tr>\n<tr>\n<td>Sun Pharma<\/td>\n<td>1,890.80<\/td>\n<td>1,862.90<\/td>\n<td>+27.90<\/td>\n<td>+1.50%<\/td>\n<\/tr>\n<tr>\n<td>Divi&#8217;s Laboratories<\/td>\n<td>6,839.00<\/td>\n<td>6,787.50<\/td>\n<td>+51.50<\/td>\n<td>+0.76%<\/td>\n<\/tr>\n<tr>\n<td>Nifty Pharma Index<\/td>\n<td>25,191.20<\/td>\n<td>24,762.90<\/td>\n<td>+428.30<\/td>\n<td>+1.73%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The divergence between Nifty Pharma (+1.73%) and Nifty IT (-1.80%) is being driven by sector-specific macro sensitivities. IT companies derive 60-80% of their revenue from North American clients, making them highly sensitive to US corporate IT spending cycles, client budget decisions, and the impact of a stronger dollar on revenue realisation. Pharmaceutical companies, by contrast, earn significant revenue from domestic Indian prescription volumes (which grow 8-12% annually irrespective of global macro) and US generic drug approvals (where the USFDA approval pipeline is independent of Fed policy).<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Drivers_of_Todays_Rally\"><\/span><strong>Key Drivers of Today&#8217;s Rally<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Track Nifty Pharma and Pharma Stocks Live on Univest Screener<\/strong><\/a><\/p>\n<h3><span class=\"ez-toc-section\" id=\"1_Cipla_Leads_the_Pharma_Pack_with_251_Gain\"><\/span><strong>1. Cipla Leads the Pharma Pack with 2.51% Gain<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Cipla&#8217;s 2.51% advance to Rs 1,451.20 makes it the top large-cap pharma gainer today. The company has a strong US business driven by complex inhalation generics (Advair equivalent, ProAir equivalent) and oral solid dosage generics from its Goa and Indore facilities. Complex inhalation drugs carry significantly higher margins than commodity generics, supporting Cipla&#8217;s earnings quality. The company&#8217;s North America revenue has been growing ahead of the segment average, and new product approvals in the inhaler segment could provide further upside to the Cipla story beyond today&#8217;s session.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_Dr_Reddys_and_Sun_Pharma_The_Nifty_Pharma_Pillars\"><\/span><strong>2. Dr Reddy&#8217;s and Sun Pharma: The Nifty Pharma Pillars<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Dr Reddy&#8217;s (+1.68% to Rs 1,312) and Sun Pharma (+1.50% to Rs 1,891) are the two largest components of the index by weighting, and their combined positive performance today is a key driver of the 1.73% advance. Dr Reddy&#8217;s has a diversified revenue mix across US generics, Russia\/CIS branded generics, and a growing biosimilars pipeline. Sun Pharma benefits from its US specialty dermatology franchise (Ilumya, Levulan) which generates premium margins compared to commodity generic drugs. Both stocks are consensus Nifty Pharma and Nifty 50 outperformers today.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_Defensive_Rotation_Narrative_IT_Outflows_Fund_Pharma_Inflows\"><\/span><strong>3. Defensive Rotation Narrative: IT Outflows Fund Pharma Inflows<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The defensive rotation trade is being accelerated by the Kospi crash today (-5.69%) and the global AI semiconductor trade unwinding. Investors who are reducing exposure to high-PE technology stocks (including Indian IT) are reallocating to sectors with lower equity risk premiums and more visible earnings growth. The pharma sector fits this requirement well: domestic formulation growth is driven by India&#8217;s ageing population, rising healthcare awareness, and government health insurance scheme expansion \u2014 all independent of global macro cycles.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Nifty Pharma is at 25,191 (+1.73%) on June 23, 2026, led by Cipla (+2.51%), Dr Reddy&#8217;s (+1.68%), and Sun Pharma (+1.50%). The index is outperforming the Nifty 50 by 1.73 percentage points and Nifty IT by 3.53 percentage points today, reflecting classic defensive rotation. Track this index and component stocks live on Univest. Consult a SEBI-registered advisor before investing.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Nifty Pharma and pharma stocks live with research on Univest.<\/em><\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> All data and stock prices are sourced from publicly available information and live exchange feeds as of June 23, 2026. This may not be accurate. Verify with NSE (nseindia.com) and BSE (bseindia.com) before investing. Securities are subject to market risk. Educational content only. Not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_Nifty_Pharma_rising_today\"><\/span><strong>Why is Nifty Pharma rising today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Nifty Pharma is rising 1.73% to 25,191 on June 23, 2026 primarily due to defensive rotation: investors are reducing exposure to IT stocks (Nifty IT -1.80%) and reallocating to healthcare names with domestic revenue visibility and an active US generics approval pipeline. Cipla (+2.51%), Dr Reddy&#8217;s (+1.68%), and Sun Pharma (+1.50%) are the leading contributors.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Nifty_Pharma_today\"><\/span><strong>What is Nifty Pharma today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Nifty Pharma is at 25,191.20 on June 23, 2026, up 1.73% (+428.30 points) from the previous close of 24,762.90. The index hit a session high of 25,294.50. It is the best-performing sectoral index today, contrasting sharply with Nifty IT which is down 1.80%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_pharma_stocks_are_rising_today\"><\/span><strong>Which pharma stocks are rising today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The top Nifty Pharma gainers today are Cipla (+2.51% to Rs 1,451), Dr Reddy&#8217;s (+1.68% to Rs 1,312), Sun Pharma (+1.50% to Rs 1,891), and Divi&#8217;s Laboratories (+0.76% to Rs 6,839). All four are among the top Nifty 50 gainers today.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_Cipla_rising\"><\/span><strong>Why is Cipla rising?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Cipla is rising 2.51% to Rs 1,451.20 on June 23, 2026, as the top Nifty Pharma gainer today. The stock is benefiting from defensive rotation out of IT stocks and its own strong US business in complex inhalation generics, which carry premium margins versus commodity generics.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_Nifty_IT_falling_while_Nifty_Pharma_rises\"><\/span><strong>Why is Nifty IT falling while Nifty Pharma rises?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Nifty IT is down 1.80% while Nifty Pharma gains 1.73% because the two sectors have opposite macro sensitivities. IT revenue is heavily US-linked and affected by rate cycles, tech spending trends, and dollar strength. Pharmaceutical domestic revenue grows independent of these factors. Defensive investors are selling IT and buying pharma today.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Sun_Pharmas_performance_today\"><\/span><strong>What is Sun Pharma&#8217;s performance today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Sun Pharma is up 1.50% to Rs 1,890.80 on June 23, 2026. India&#8217;s largest pharma company benefits from its US specialty dermatology drugs (Ilumya, Levulan) and branded generics across emerging markets. It is among the top Nifty Pharma contributors today.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Nifty_Pharma_a_good_investment\"><\/span><strong>Is Nifty Pharma a good investment?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Nifty Pharma is a defensive sector with earnings driven by domestic prescriptions, US generics approvals, and emerging market branded generics. The sector benefits from India&#8217;s growing healthcare spend and USFDA approval pipeline. Investors can access the index through pharma ETFs or individual stock selection. Consult a SEBI-registered advisor for personalised guidance.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Divis_Laboratories\"><\/span><strong>What is Divi&#8217;s Laboratories?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Divi&#8217;s Laboratories is a contract research and manufacturing services (CRAMS) company that supplies active pharmaceutical ingredients (APIs) to global pharmaceutical multinationals. The stock is up 0.76% to Rs 6,839 as part of today&#8217;s Nifty Pharma rally. Divi&#8217;s business is driven by long-term supply contracts rather than product launches, providing revenue stability.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Why is Nifty Pharma rising today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Nifty Pharma is rising 1.73% to 25,191 on June 23, 2026 primarily due to defensive rotation: investors are reducing exposure to IT stocks (Nifty IT -1.80%) and reallocating to healthcare names with domestic revenue visibility and an active US generics approval pipeline. Cipla (+2.51%), Dr Reddy's (+1.68%), and Sun Pharma (+1.50%) are the leading contributors.\"}},{\"@type\":\"Question\",\"name\":\"What is Nifty Pharma today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Nifty Pharma is at 25,191.20 on June 23, 2026, up 1.73% (+428.30 points) from the previous close of 24,762.90. The index hit a session high of 25,294.50. It is the best-performing sectoral index today, contrasting sharply with Nifty IT which is down 1.80%.\"}},{\"@type\":\"Question\",\"name\":\"Which pharma stocks are rising today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The top Nifty Pharma gainers today are Cipla (+2.51% to Rs 1,451), Dr Reddy's (+1.68% to Rs 1,312), Sun Pharma (+1.50% to Rs 1,891), and Divi's Laboratories (+0.76% to Rs 6,839). All four are among the top Nifty 50 gainers today.\"}},{\"@type\":\"Question\",\"name\":\"Why is Cipla rising?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Cipla is rising 2.51% to Rs 1,451.20 on June 23, 2026, as the top Nifty Pharma gainer today. The stock is benefiting from defensive rotation out of IT stocks and its own strong US business in complex inhalation generics, which carry premium margins versus commodity generics.\"}},{\"@type\":\"Question\",\"name\":\"Why is Nifty IT falling while Nifty Pharma rises?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Nifty IT is down 1.80% while Nifty Pharma gains 1.73% because the two sectors have opposite macro sensitivities. IT revenue is heavily US-linked and affected by rate cycles, tech spending trends, and dollar strength. Pharmaceutical domestic revenue grows independent of these factors. Defensive investors are selling IT and buying pharma today.\"}},{\"@type\":\"Question\",\"name\":\"What is Sun Pharma's performance today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Sun Pharma is up 1.50% to Rs 1,890.80 on June 23, 2026. India's largest pharma company benefits from its US specialty dermatology drugs (Ilumya, Levulan) and branded generics across emerging markets. It is among the top Nifty Pharma contributors today.\"}},{\"@type\":\"Question\",\"name\":\"Is Nifty Pharma a good investment?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Nifty Pharma is a defensive sector with earnings driven by domestic prescriptions, US generics approvals, and emerging market branded generics. The sector benefits from India's growing healthcare spend and USFDA approval pipeline. Investors can access the index through pharma ETFs or individual stock selection. Consult a SEBI-registered advisor for personalised guidance.\"}},{\"@type\":\"Question\",\"name\":\"What is Divi's Laboratories?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Divi's Laboratories is a contract research and manufacturing services (CRAMS) company that supplies active pharmaceutical ingredients (APIs) to global pharmaceutical multinationals. The stock is up 0.76% to Rs 6,839 as part of today's Nifty Pharma rally. Divi's business is driven by long-term supply contracts rather than product launches, providing revenue stability.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nifty Pharma Jumps Nearly 2% on June 23, 2026: Dr Reddy&#8217;s, Sun Pharma and Cipla Lead Gains. June 23, 2026.<\/p>\n","protected":false},"author":34,"featured_media":127643,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[4801],"class_list":["post-127628","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-nifty-pharma-jumps"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1782201194:23"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["80"],"rank_math_title":["Nifty Pharma Jumps Nearly 2% on June 23: Dr Reddy's, Sun Pharma and Cipla Lead Gains"],"rank_math_description":["Nifty Pharma rises 1.73% to 25,191 on June 23, 2026. Cipla +2.51%, Dr Reddy's +1.68%, Sun Pharma +1.50%, Divi's Lab +0.76%. Pharma stocks dominate Nifty 50 gainers list on defensive rotation."],"rank_math_focus_keyword":["Nifty Pharma"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["127643"],"_edit_last":["23"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["20357"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/06\/Nifty-Pharma-Jumps-Nearly-2.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/127628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=127628"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/127628\/revisions"}],"predecessor-version":[{"id":127644,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/127628\/revisions\/127644"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/127643"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=127628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=127628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=127628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}